Blood:MiR-125a和miR-34a可预测CLL患者是否发生Richter综合征

2018-09-22 MedSci MedSci原创

中心点:MiR-125a-5p高表达或miR-34a-5p低表达可预测约50%的RS,假阳性率9%。MiR-125a-5p和miR-34a-5p可作为预测CLL患者有无RS发展的标志物。摘要:慢性淋巴细胞白血病(CLL)是一种最常见的成人白血病。其特点是CD19+/CD5+淋巴细胞积累,预后多变。Richter综合征(RS)是CLL患者的一种致命性并发症,可导致侵袭性B细胞淋巴瘤。迄今为止,尚无检

中心点:

MiR-125a-5p高表达或miR-34a-5p低表达可预测约50%的RS,假阳性率9%。

MiR-125a-5p和miR-34a-5p可作为预测CLL患者有无RS发展的标志物。

摘要:

慢性淋巴细胞白血病(CLL)是一种最常见的成人白血病。其特点是CD19+/CD5+淋巴细胞积累,预后多变。Richter综合征(RS)是CLL患者的一种致命性并发症,可导致侵袭性B细胞淋巴瘤。迄今为止,尚无检验可预测RS的发生。鉴于microRNA表达的癌变可预测多种癌症的进展侵袭,Veronica Balatti等人探究是否存在特异性的microRNA调控异常,可预测CLL患者发生RS。

研究人员将49位出现RS的CLL患者的样本的microRNA的表达水平与59位无RS的CLL患者的样本的microRNA的表达水平进行对比,发现miR-125a-5p高表达或miR-34a-5p低表达可预测约50%的RS,假阳性率9%。与对照组相比,RS患者miR-125a-5p的表达水平升高了20倍、miR-34a-5p的表达水平降低了21倍。

因此,研究人员推测miR-125a-5p和miR-34a-5p可作为预测RS的标志物,有潜力为临床医生提供有用的信息,有助于为CLL患者制定最佳的治疗方案。


原始出处:

Veronica Balatti, et al. MiR-125a and MiR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood  2018  :blood-2018-04-845115;  doi: https://doi.org/10.1182/blood-2018-04-845115

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1927585, encodeId=ae3f192e58521, content=<a href='/topic/show?id=f6ff154653c' target=_blank style='color:#2F92EE;'>#Richter综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15465, encryptionId=f6ff154653c, topicName=Richter综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Wed May 22 12:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930650, encodeId=0af0193065088, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Mar 16 13:40:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943501, encodeId=91e11943501d5, content=<a href='/topic/show?id=0fa31188829' target=_blank style='color:#2F92EE;'>#miR-34a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11888, encryptionId=0fa31188829, topicName=miR-34a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Mar 29 18:40:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316361, encodeId=326513163610d, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Sep 24 05:40:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431331, encodeId=bb3b1431331c7, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Sep 24 05:40:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346292, encodeId=2c593462926d, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun Sep 23 10:26:14 CST 2018, time=2018-09-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1927585, encodeId=ae3f192e58521, content=<a href='/topic/show?id=f6ff154653c' target=_blank style='color:#2F92EE;'>#Richter综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15465, encryptionId=f6ff154653c, topicName=Richter综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Wed May 22 12:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930650, encodeId=0af0193065088, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Mar 16 13:40:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943501, encodeId=91e11943501d5, content=<a href='/topic/show?id=0fa31188829' target=_blank style='color:#2F92EE;'>#miR-34a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11888, encryptionId=0fa31188829, topicName=miR-34a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Mar 29 18:40:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316361, encodeId=326513163610d, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Sep 24 05:40:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431331, encodeId=bb3b1431331c7, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Sep 24 05:40:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346292, encodeId=2c593462926d, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun Sep 23 10:26:14 CST 2018, time=2018-09-23, status=1, ipAttribution=)]
    2019-03-16 smallant2002
  3. [GetPortalCommentsPageByObjectIdResponse(id=1927585, encodeId=ae3f192e58521, content=<a href='/topic/show?id=f6ff154653c' target=_blank style='color:#2F92EE;'>#Richter综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15465, encryptionId=f6ff154653c, topicName=Richter综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Wed May 22 12:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930650, encodeId=0af0193065088, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Mar 16 13:40:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943501, encodeId=91e11943501d5, content=<a href='/topic/show?id=0fa31188829' target=_blank style='color:#2F92EE;'>#miR-34a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11888, encryptionId=0fa31188829, topicName=miR-34a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Mar 29 18:40:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316361, encodeId=326513163610d, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Sep 24 05:40:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431331, encodeId=bb3b1431331c7, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Sep 24 05:40:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346292, encodeId=2c593462926d, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun Sep 23 10:26:14 CST 2018, time=2018-09-23, status=1, ipAttribution=)]
    2019-03-29 xzw113
  4. [GetPortalCommentsPageByObjectIdResponse(id=1927585, encodeId=ae3f192e58521, content=<a href='/topic/show?id=f6ff154653c' target=_blank style='color:#2F92EE;'>#Richter综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15465, encryptionId=f6ff154653c, topicName=Richter综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Wed May 22 12:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930650, encodeId=0af0193065088, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Mar 16 13:40:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943501, encodeId=91e11943501d5, content=<a href='/topic/show?id=0fa31188829' target=_blank style='color:#2F92EE;'>#miR-34a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11888, encryptionId=0fa31188829, topicName=miR-34a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Mar 29 18:40:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316361, encodeId=326513163610d, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Sep 24 05:40:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431331, encodeId=bb3b1431331c7, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Sep 24 05:40:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346292, encodeId=2c593462926d, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun Sep 23 10:26:14 CST 2018, time=2018-09-23, status=1, ipAttribution=)]
    2018-09-24 diushouji
  5. [GetPortalCommentsPageByObjectIdResponse(id=1927585, encodeId=ae3f192e58521, content=<a href='/topic/show?id=f6ff154653c' target=_blank style='color:#2F92EE;'>#Richter综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15465, encryptionId=f6ff154653c, topicName=Richter综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Wed May 22 12:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930650, encodeId=0af0193065088, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Mar 16 13:40:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943501, encodeId=91e11943501d5, content=<a href='/topic/show?id=0fa31188829' target=_blank style='color:#2F92EE;'>#miR-34a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11888, encryptionId=0fa31188829, topicName=miR-34a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Mar 29 18:40:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316361, encodeId=326513163610d, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Sep 24 05:40:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431331, encodeId=bb3b1431331c7, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Sep 24 05:40:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346292, encodeId=2c593462926d, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun Sep 23 10:26:14 CST 2018, time=2018-09-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1927585, encodeId=ae3f192e58521, content=<a href='/topic/show?id=f6ff154653c' target=_blank style='color:#2F92EE;'>#Richter综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15465, encryptionId=f6ff154653c, topicName=Richter综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Wed May 22 12:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930650, encodeId=0af0193065088, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Mar 16 13:40:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943501, encodeId=91e11943501d5, content=<a href='/topic/show?id=0fa31188829' target=_blank style='color:#2F92EE;'>#miR-34a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11888, encryptionId=0fa31188829, topicName=miR-34a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Mar 29 18:40:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316361, encodeId=326513163610d, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Sep 24 05:40:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431331, encodeId=bb3b1431331c7, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Sep 24 05:40:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346292, encodeId=2c593462926d, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun Sep 23 10:26:14 CST 2018, time=2018-09-23, status=1, ipAttribution=)]
    2018-09-23 kafei

    了解一下谢谢

    0

相关资讯

Haematologica:CLL一线抢救治疗,BR pk 依鲁替尼

2018年7月,发表在《Haematologica》的由意大利、英国、西班牙等国学者进行的GIMEMA、ERIC和UK CLL FORUM研究,考察了苯达莫司汀和利妥昔单抗(BR)作为慢性淋巴细胞白血病(CLL)一线抢救治疗的有效性并与依鲁替尼进行间接比较。

Blood:Bruton酪氨酸激酶的非共价抑制剂(GDC-0853),为对依鲁替尼耐药的CLL患者带来新的希望!

依鲁替尼在临床上的成功证实了Bruton酪氨酸激酶(BTK)抑制是治疗包括慢性淋巴细胞白血病(CLL)在内的血液性恶性肿瘤的有效方案。虽然依鲁替尼可使患者获得持久性的缓解,但会产生耐药性,主要是由依鲁替尼结合位点BTK的C481突变引起。近日,Blood杂志上发表一篇文章,研究人员对新型BTK抑制剂(GDC-0853)用于治疗幼稚型和依鲁替尼耐受性CLL的预临床疗效进行评估。GDC-0853是一种

Blood:RPS15突变型慢性淋巴细胞白血病整体蛋白质合成模式和翻译保真度均发生改变

中心点:CLL的RPS15改变可诱导整体蛋白质合成和翻译保真度发生突变依赖性的变化。RPS15突变可通过蛋白质组学改变破坏细胞蛋白质稳定,主要是影响mRNA转录和细胞代谢。摘要:近期,基因组学研究发现RPS15是慢性淋巴细胞白血病(CLL)侵袭性和耐药性病例中的一种新的驱动基因。RPS15编码核糖体蛋白,其C末端保守,延伸至核糖体的解码中心。Gabriel Bretones等人发现该结构域高度保守

Blood:体外激活和依鲁替尼治疗可恢复CLL Vγ9Vδ2-T细胞的抗CLL细胞的细胞毒性作用

中心点:健康的Vγ9Vδ2-T细胞可识别裂解CLL细胞,但CLL患者来源的Vγ9Vδ2-T细胞的细胞毒性和细胞因子合成受损。用自体moDCs在体外激活Vγ9Vδ2-T细胞可逆转其功能障碍,依鲁替尼可促进产生抗肿瘤的TH1表型。摘要:自体(αβ)T细胞为基础的治疗策略用于慢性淋巴细胞白血病(CLL)的疗效一直较为温和。具有强力的抗淋巴瘤活性的细胞毒性T淋巴细胞通过主要组织相容性复合物(MHC)非依赖

Blood:CLL患者异基因造血干细胞移植:如何进行?何时进行?

异基因造血干细胞移植(allo-SCT)是高危慢性淋巴细胞白血病(CLL)的治疗选择之一,也是唯一有治愈可能的治疗手段。随着B细胞受体抑制剂(BCRi)BCL2抑制剂的出现,CLL患者的选择和行allo-SCT的合适时机也变得困难。英国Gribben教授在BLOOD杂志上讨论了高危CLL的不同治疗方法,以及新药时代如何使用allo-SCT治疗CLL。

JCO:中位缓解持续时间33.2个月!Venetoclax使伴del(17p)难治复发CLL患者获持久缓解

伴17号染色体缺失(del[17p])或TP53基因突变的慢性淋巴细胞白血病(CLL)患者预后差,Venetoclax可有效提高该类患者缓解率,但早期临床试验结果尚不能明确Venetoclax应答持久性及安全性等问题。近日,JCO杂志发布了Venetoclax治疗伴del(17p)难治复发CLL患者的最新随访结果,旨在评估Venetoclax应答持久性、安全性及患者微小残留灶(MRD)情况。